BioXcel Therapeutics, Inc. (BTAIQ) stock
BTAIQOTCPharmaceutical PreparationsFiscal year ends December 31
$0.03−0.00 (-13.49%)
Close on Oct 19, 2026Market cap $757.50KP/E –Yield –
BioXcel Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
BioXcel Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $21.56M, down 16.5% year over year. For fiscal 2025 it was $30.25M, down 0.6% from the year before. The highest annual figure on record is $91.24M in fiscal 2022.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $30.25M | -0.6% |
| FY2024 | Dec 31, 2024 | $30.44M | -63.9% |
| FY2023 | Dec 31, 2023 | $84.33M | -7.6% |
| FY2022 | Dec 31, 2022 | $91.24M | +73.1% |
| FY2021 | Dec 31, 2021 | $52.71M | -9.1% |
| FY2020 | Dec 31, 2020 | $58.00M | +124.8% |
| FY2019 | Dec 31, 2019 | $25.80M | +77.2% |
| FY2018 | Dec 31, 2018 | $14.56M | +441.2% |
| FY2017 | Dec 31, 2017 | $2.69M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $3.16M | -69.1% |
| Q1 FY2026 | Mar 31, 2026 | $2.96M | -35.1% |
| Q4 FY2025 | Dec 31, 2025 | $6.70M | +13.6% |
| Q3 FY2025 | Sep 30, 2025 | $8.74M | +71.3% |
| Q2 FY2025 | Jun 30, 2025 | $10.26M | +27.7% |
| Q1 FY2025 | Mar 31, 2025 | $4.55M | -60.1% |
| Q4 FY2024 | Dec 31, 2024 | $5.90M | -40.6% |
| Q3 FY2024 | Sep 30, 2024 | $5.10M | -74.0% |
| Q2 FY2024 | Jun 30, 2024 | $8.03M | -70.2% |
| Q1 FY2024 | Mar 31, 2024 | $11.40M | -59.0% |
| Q4 FY2023 | Dec 31, 2023 | $9.93M | -69.4% |
| Q3 FY2023 | Sep 30, 2023 | $19.62M | -11.1% |
| Q2 FY2023 | Jun 30, 2023 | $26.97M | +50.6% |
| Q1 FY2023 | Mar 31, 2023 | $27.80M | +49.8% |
| Q4 FY2022 | Dec 31, 2022 | $32.46M | +159.2% |
| Q3 FY2022 | Sep 30, 2022 | $22.06M | +84.9% |
| Q2 FY2022 | Jun 30, 2022 | $17.91M | +32.5% |
| Q1 FY2022 | Mar 31, 2022 | $18.56M | +25.9% |
| Q4 FY2021 | Dec 31, 2021 | $12.53M | +9.9% |
| Q3 FY2021 | Sep 30, 2021 | $11.93M | -26.9% |
| Q2 FY2021 | Jun 30, 2021 | $13.51M | -24.6% |
| Q1 FY2021 | Mar 31, 2021 | $14.74M | +19.2% |
| Q4 FY2020 | Dec 31, 2020 | $11.40M | +75.5% |
| Q3 FY2020 | Sep 30, 2020 | $16.32M | +129.1% |
| Q2 FY2020 | Jun 30, 2020 | $17.91M | +175.2% |
| Q1 FY2020 | Mar 31, 2020 | $12.37M | +118.0% |
| Q4 FY2019 | Dec 31, 2019 | $6.50M | +7.9% |
| Q3 FY2019 | Sep 30, 2019 | $7.12M | +86.4% |
| Q2 FY2019 | Jun 30, 2019 | $6.51M | +265.3% |
| Q1 FY2019 | Mar 31, 2019 | $5.67M | +93.1% |
| Q4 FY2018 | Dec 31, 2018 | $6.02M | +322.0% |
| Q3 FY2018 | Sep 30, 2018 | $3.82M | +517.3% |
| Q2 FY2018 | Jun 30, 2018 | $1.78M | +449.7% |
| Q1 FY2018 | Mar 31, 2018 | $2.94M | +815.3% |
| Q4 FY2017 | Dec 31, 2017 | $1.43M | – |
| Q3 FY2017 | Sep 30, 2017 | $619.00K | – |
| Q2 FY2017 | Jun 30, 2017 | $324.00K | – |
| Q1 FY2017 | Mar 31, 2017 | $321.00K | – |
See a number that looks wrong?